Monoclonal Protein Study, Random, Urine
Monoclonal proteins, also known as M-proteins, are abnormal immunoglobulins or their fragments produced by a single clone of plasma cells. Unlike normal circumstances in which plasma cells differentiate into a diverse variety of clones, conditions such as multiple myeloma, Waldenström’s macroglobulinemia, and MGUS result in the proliferation of a single plasma cell clone, which secretes large quantities of identical immunoglobulins. These antibodies are easily detected in serum protein electrophoresis in the gamma region as monoclonal spikes. The unregulated clones can secrete large quantities of IgG, IgA, and, rarely, IgM. In some cases, only light chains of IgG—kappa and lambda light chains—are secreted. All conditions that result from plasma cell dysregulation are collectively termed plasma cell dyscrasias.
Multiple myeloma is the second most frequently occurring hematologic malignancy originating from the B-cell population and is a leading cause of death worldwide. Excessive monoclonal antibody production in multiple myeloma can result in kidney injury, amyloid deposits, lytic bone disease, and abnormal blood coagulation. Quantitation of serum monoclonal protein by electrophoresis or mass spectrometry helps in diagnosis and monitoring of treatment response.
MGUS is a benign condition in which comparatively smaller amounts of monoclonal proteins are produced with a lower frequency of organ injury. Monoclonal protein levels in MGUS are detectable, though lower in concentration compared to multiple myeloma.
Waldenström’s macroglobulinemia, on the other hand, is a rare B-cell lymphoproliferative disorder characterized by excess IgM production. Spikes in the gamma region with monoclonal IgM detection can confirm the diagnosis. Monoclonal protein testing is highly effective for diagnosing and monitoring plasma cell dyscrasias.
- As an aid in the diagnosis and management of multiple myeloma, MGUS, and Waldenstrom macroglobulinemia
- Detection of minimal residual disease, disease remission, or relapse
Increased M-protein Levels May Indicate:
- Multiple Myeloma
- Monoclonal gammopathy of undetermined significance (MGUS)
- Waldenström’s Macroglobulinemia
- Primary Systemic Amyloidosis (AL)
- CLL with plasmacytic differentiation
- Smoldering Myeloma
Decreased/Absent M-protein in Presence of Symptoms May Suggest:
- Non-secretory Multiple Myeloma
- Hypogammaglobulinemia (e.g., primary immunodeficiency, nephrotic syndrome)
| Age | IgG (mg/dL) | IgA (mg/dL) | IgM (mg/dL) |
|---|---|---|---|
| 0–<5 mo | 100–334 | 7–37 | 26–122 |
| 5–<9 mo | 164–588 | 16–50 | 32–132 |
| 9–<15 mo | 246–904 | 27–66 | 40–143 |
| 15–<24 mo | 313–1,170 | 36–79 | 46–152 |
| 2–<4 y | 295–1,156 | 27–246 | 37–184 |
| 4–<7 y | 386–1,470 | 29–256 | 37–224 |
| 7–<10 y | 462–1,682 | 34–274 | 38–251 |
| 10–<13 y | 503–1,719 | 42–295 | 41–255 |
| 13–<16 y | 509–1,580 | 52–319 | 45–244 |
| 16–<18 y | 487–1,327 | 60–337 | 49–201 |
| ≥18 y | 767–1,590 | 61–356 | 37–286 |
Random urine collected in a sterile urine cup.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 28 days
- Clin Chem Lab Med. 2021 Aug 16;59(12):1963-1971. [PMID: 34392637]
- Clin Cancer Res. 2024 Mar 15;30(6):1131-1142. [PMID: 38170583]
- Front Oncol. 2022 Dec 15;12:1073479. [PMID: 36591514]
- World J Clin Cases. 2023 Aug 26;11(24):5643-5652. [PMID: 37727707]
- Clin Chem Lab Med. 2023 Oct 12;62(3):540-550. [PMID: 37823394]